Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 70.04% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.

English

Regional settings

Entity•Capital Com UK LimitedAuthorised and regulated by the Financial Conduct Authority (FCA)

My account

Home Markets SharesXeris Biopharma Holdings, Inc.

Trade Xeris Biopharma Holdings, Inc. - XERS CFD

Summary Historical Data

Trading Conditions

Spread

0.05

Long position overnight fee

Long position overnight fee

Margin. Your investment	$1,000.00
Overnight fee Charges from full value of position	-0.026179 % (-$1.05)

Trade size with leverage ~ $5,000.00

Short position overnight fee ~ $4,000.00

Go to platform

-0.026179%

Short position overnight fee

Short position overnight fee

Margin. Your investment	$1,000.00
Overnight fee Charges from full value of position	0.003957 % ($0.16)

Trade size with leverage ~ $5,000.00

Short position overnight fee ~ $4,000.00

Go to platform

0.003957%

Overnight fee time

21:00 (UTC)

Currency

USD

Min traded quantity

Margin

Stock exchange

United States of America

Commission on trade¹

¹Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats

Prev. Close	1.83
Open	1.88
1-Year Change	-18.97%
Day's Range	1.82 - 1.89

Xeris Biopharma Holdings, Inc. Company profile

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. It markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for primary periodic paralysis. The company also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was founded in 2005 and is headquartered in Chicago, Illinois.